GSK Advances Arthritis Candidate into Phase III, Triggering €22M Milestone Payment to MorphoSys
GlaxoSmithKline (GSK) has launched a Phase III program for the rheumatoid arthritis candidate it is developing under license from MorphoSys—triggering a milestone payment to MorphoSys of €...